Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk's Wegovy wins FDA approval for heart health benefits, in move that could expand insurance coverage
02:10pm, Friday, 08'th Mar 2024
Novo Nordisk's Wegovy wins FDA approval for heart health benefits, in move that could expand insurance coverage
Novo Nordisk CEO says experimental weight loss pill could become a best in class drug
12:37pm, Friday, 08'th Mar 2024
Lars Fruergaard Jørgensen's remarks came one day after Novo Nordisk impressed investors with early-stage trial data on amycretin.
Novo Nordisk (NVO) Up on Upbeat Data From New Obesity Pill Study
11:06am, Friday, 08'th Mar 2024
Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day.
Novo Nordisk hopes to launch experimental obesity drug this decade
07:14am, Friday, 08'th Mar 2024
Novo Nordisk's head of development on Friday told Reuters he was very comfortable the drugmaker would be able to launch the pill version of its experimental weight loss drug amycretin this decade.
Novo Nordisk CEO says innovation in obesity may justify higher price in some segments
06:09am, Friday, 08'th Mar 2024
Novo Nordisk's CEO expects more people to take obesity drugs as prices fall over time, he told Reuters on Friday, adding that new generations of the medicine will justify higher prices in some segment
Tesla Stock Is Rising. Novo Nordisk Overtakes the EV Maker's Valuation.
06:00am, Friday, 08'th Mar 2024
The stock move comes as Novo Nordisk, maker of obesity drug Wegovy, overtook Tesla's market value Thursday.
Compounded semaglutide poses serious U.S. health issue, Novo Nordisk CEO says
05:52am, Friday, 08'th Mar 2024
Novo Nordisk's CEO on Friday said compounded semaglutide in the United States is a serious health issue.
Novo Nordisk market cap surpasses Tesla on new obesity pill trial data
04:53am, Friday, 08'th Mar 2024
Wegovy obesity drug maker Novo Nordisk surpassed Tesla in market value Thursday after fresh early trial data showed positive results for its new experimental weight loss pill.
Novo Nordisk seeks acquisitions to boost obesity, diabetes pipeline
04:45am, Friday, 08'th Mar 2024
Novo Nordisk will prioritise acquisitions that can complement its pipeline of obesity and diabetes drugs rather than buying supply chain companies, the Danish group's head of business development told
Novo Nordisk hopes to launch experimental obesity drug "within this decade"
04:04am, Friday, 08'th Mar 2024
Novo Nordisk's head of development on Friday told Reuters he was very comfortable the drugmaker would be able to launch the pill version of its experimental weight loss drug amycretin this decade.
Novo Nordisk shares overhyped? One investment bank certainly thinks they are overvalued
03:52am, Friday, 08'th Mar 2024
Novo Nordisk (NYSE:NVO)'s shares are significantly overvalued, based on analysis shared by the American bank Jefferies in a note to clients. It said that, as ever, Novo delivered its 'usual polished p
Novo Nordisk (NVO) Hits High After Weight Loss Trial
01:06pm, Thursday, 07'th Mar 2024
Novo Nordisk (NVO) shares opened at an all-time high after a promising weight loss trial. Jeff Pierce discusses this as Eli Lilly (LLY) shares fall after Novo Nordisk's weight loss trial shows positiv
Ozempic maker Novo Nordisk surges past Tesla with market value of $566B
11:52am, Thursday, 07'th Mar 2024
Novo's shares have risen more than three-fold since June 2021 when it launched Wegovy in the US, last year becoming Europe's most valuable listed company, ahead of LVMH.
Why Novo Nordisk Stock Is Jumping Today (Hint: It's Not Because of Ozempic or Wegovy)
11:49am, Thursday, 07'th Mar 2024
Novo Nordisk revealed results from a phase 1 study of amycretin at an investor event on Thursday. Patients taking the experimental drug achieved an average weight loss of 13.1% after 12 weeks.
Weight loss drugs: Novo Nordisk stock hits record high on new data
11:45am, Thursday, 07'th Mar 2024
Shares of Novo Nordisk (NVO) have hit a record high on phase 1 trial data from Amycretin, its latest weight loss product. The new drug shows over 13% weight loss in users after 12 weeks of use, more t
